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Preliminary experience in an italian 
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Federica Rossi1,2*, Simona Cancedda1, Vito Ferdinando Leone1, Carla Rohrer Bley1,3  
and Paola Laganga1
1 Centro Oncologico Veterinario, Sasso Marconi, Italy, 2 Clinica Veterinaria dell’Orologio, Sasso Marconi, Italy, 3 Division of 
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The aim of the study was to evaluate the efficacy and toxicity of a low-dose radiotherapy 
treatment in dogs with osteoarthritis (OA). Inclusion criteria were dogs affected by OA 
of one or multiple joints, with lameness, previously treated with medical therapy and 
referred for radiotherapy because of chronic unresponsive pain. After suspension of 
medical therapy, dogs underwent external beam radiotherapy treatments delivered in 
three fractions of 2 Gy each. Four of these dogs had one (three dogs) to four (one dog) 
additional courses of radiation. Medical records were reviewed and follow-up information 
was collected by clinical recheck and owners interview. Twenty-five dogs matched the 
inclusion criteria; among them, 21 had one course of RT and 4 underwent multiple 
treatments, respectively 218, 266, 39, and 1,384 days after the first treatment. Clinical 
improvement was observed in 92% of patients with median benefit duration of 356 days 
after the first treatment, and 418 days after the second treatment. No side effects were 
recorded. In this group of patients, radiotherapy was effective, well tolerated, and repeat-
able, leading to an improvement of quality of life in dogs with degenerative joint disease 
unresponsive to medical treatments.
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inTrODUcTiOn
In dogs, osteoarthritis (OA) is a frequent, often under-diagnosed and non-adequately treated chronic 
disease (1). OA is a progressive joint disease characterized by pain, reduced joint range of motion 
(ROM), cartilage destruction, and bone remodeling (2). Inflammation of the synovial cells and 
chondrocytes dysfunction are responsible for the biochemical changes behind this condition, with 
subsequent release of cytokines, free radicals and prostaglandins, reduced proteoglycans production, 
and increased lysosomal enzyme production (2, 3). Vasodilation, increased vascular permeability, 
and pain receptor stimulation result in joint swelling, increased local temperature, crepitus, and pain 
(2). Disease chronicity is characterized by muscular atrophy and decreased ROM (2). Radiographic 
changes include soft tissue thickening due to joint effusion and capsular fibrosis, subcondral bone 
sclerosis, and periarticular osteophytes (2).
TaBle 1 | Lameness and pain score system used to assess response to low-
dose radiation therapy (22, 23).
category and score clinical signs
lameness
1 Stands, walks, and trots normally
2 Stands normally, slight lameness under special 
circumstances or inconsistent lameness when trotting
3 Stands normally, obvious lameness when trotting, 
consistent lameness when walking
4 Abnormal position while standing, obvious lameness 
under any circumstances
5 Reluctant to rise and walk, intermittent or continuous 
non-weight-bearing lameness
Pain on palpation
1 No signs of pain during palpation of affected joint
2 Mild pain during palpation; dog turn heads in recognition
3 Moderate pain during palpation; dog pulls limb away
4 Severe pain during palpation; dog vocalizes or becomes 
aggressive
5 Dog will not allow examiner to evaluate the joint
2
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The goal of OA treatment is to decrease joint effusion and 
cartilage damage, slower the fibrotic process and finally control 
pain, and is based on the combination of medical therapy, weight 
control, nutritional supports, and physical rehabilitation (1, 2, 
4, 5). Non-steroid and steroid anti-inflammatory drugs and opiates 
are often used in dogs affected by OA, alone or in combination, to 
control clinical symptoms; however, they are often insufficient to 
provide adequate mobility and good quality of life (QoL) and are 
frequently associated with gastrointestinal and renal side effects 
if used in the long period (6, 7). Other innovative treatments, 
including autologous platelet therapy and mesenchymal cells 
administration, have been proposed in veterinary medicine with 
encouraging preliminary results (8–11).
Low-dose radiation therapy (LDRT) is a well-known treat-
ment in human medicine to control chronic unresponsive pain 
in the long term; partial or complete responses in patients with 
painful arthrosis have been reported in 24–100% of treated cases, 
depending on the study (12–14). The radiobiological mechanism 
in inflammatory diseases of LDRT has been investigated and con-
firmed, however, not completely understood (15, 16). The anti-
inflammatory and analgesic effect is the result of a combination of 
cell activity modulation (reduced adhesion of blood mononuclear 
cells to endothelial cell, macrophages, and granulocytes activity 
regulation) and anti-inflammatory factors production (lowered 
production of cytokine, nitric oxide, and reactive oxygen species) 
(16). Similar clinical results are reported in horses, where a dose 
raging between 5 and 15 Gy has been used to treat degenerative 
joint diseases (DJD) (17, 18). First experiences of local radiation 
therapy by intra-articular administration of β-emitting radio-
nuclides are reported in dogs, showing improvement in clinical 
signs and no significant side effects (19, 20). Recently, a single-
fraction 10 Gy RT protocol has been investigated in five Labrador 
Retrievers affected by elbow OA, with short-term clinical benefit 
and improved weight bearing in the affected limb (21). However, 
there is no similar information on long-term external-beam RT 
effect in different diseased joints in dogs.
The aim of this retrospective study was to evaluate the response 
to LDRT in a cohort of dogs affected by DJD of single or multiple 
joints after interruption of medical therapy. It was hypothesized 
that RT as single treatment modality would provide an improve-
ment in lameness severity and QoL.
MaTerials anD MeThODs
inclusion criteria
Dogs affected by OA of one or multiple joints presented to the 
Centro Oncologico Veterinario between May 2009 and December 
2016 and treated with LDRT were retrospectively included in the 
study. Dogs had to be affected by various grades of lameness, vis-
ited by a veterinarian orthopedic, having radiographic evidence 
of OA, and being unresponsive to drugs or other types of treat-
ments. Medical records were reviewed to retrieve demographic 
information [breed sex, age, weight, and body condition score 
(BCS)], results of orthopedic evaluation, and clinical examination 
at the RT center, previous medical and non-medical treatments, 
results of blood tests, and radiographic examination. Lameness 
location during walking and trotting, lameness (grades 1–5) and 
evaluation of pain during palpation (grades 1–5) were recorded 
(Table 1) using previously validated grading systems (22, 23).
rT Treatment
Dogs were treated under general anesthesia in dorsal, sternal, or 
lateral recumbency, depending on the anatomic location of the 
affected joint(s), with electron beam radiation delivered using a 
linear accelerator (Clinac DMX; Varian Medical Systems, Palo 
Alto, CA, USA). Treatment planning was performed by hand 
calculation. Radiographs of the joint taken in two orthogonal 
projections were used to calculate the thickness of the joint and 
the field size, in order to include the entire joint in the treatment 
field. The prescribed dose was 6  Gy divided in three fractions 
of 2  Gy each over three consecutive days or on an alternate 
scheduling (Monday, Thursday, Friday), delivered with a single 
9–15  MeV electron field. The 90% isodose line was chosen to 
encompass this target volume and for dose normalization (24). 
Source–surface distance was set at 100 cm.
Treatment response was evaluated by a clinical recheck 
3 weeks after the end of RT, and repeated every 3 months there-
after. Partial response was defined as lameness improvement of at 
least one grade, complete response was considered if the dog was 
free of lameness at the 3 weeks rechecks. Before the treatment and 
3 weeks after the end of RT, owners were asked to answer a chronic 
pain index questionnaire. The questionnaire was in Italian and 
included 11 questions with 5 answers each based on a 5 points 
descriptive scale, testing animal’s behavior and locomotion, as 
previously described (25) (Table 2) The answer to those questions 
were assigned index scores from 0 to 4. The total chronic pain 
index score ranged from 0 to 44, where 0 represented lack of pain 
(normal) and 44 the highest pain level. Median score for dogs 
before and after treatment was calculated and compared through 
the Wilcoxon matched-pairs signed rank test. Treatment toxicity 
was evaluated and graded based on the Veterinary Radiation 
Therapy Oncology Group Criteria (26).
TaBle 2 | Pain assessment questionnaire including 11 questions with 5 answers (19).
assessed item 0 1 2 3 4
Mood Very alert Alert Neither alert nor indifferent Indifferent Very indifferent
Dog’s willingness to play and games Very willingly Willingly Reluctantly Very reluctantly Does not at all
Vocalization (audible complaining) Never Hardly ever Sometimes Often Very often
Dog’s willingness to walk Very willingly Willingly Reluctantly Very reluctantly Does not at all
Dog’s willingness to trott Very willingly Willingly Reluctantly Very reluctantly Does not at all
Dog’s willingness to gallopp Very willingly Willingly Reluctantly Very reluctantly Does not at all
Dog’s willingness to jump Very willingly Willingly Reluctantly Very reluctantly Does not at all
Dog’s ease in lying down With great ease Easily Neither easily nor with difficulty With difficulty With great difficulty
Dog’s ease in getting up With great ease Easily Neither easily nor with difficulty With difficulty With great difficulty
Dog’s difficulty in movement after rest Never Hardly ever Sometimes Often Very often or always
Movement after major exercise Never Hardly ever Sometimes Often Very often or always
Owners were asked to score dog’s pain from 0 to 4 before and 3 weeks after RT treatment. Differences in the lameness and pain scores at baseline and after RT were assessed with 
Wilcoxon matched-pairs signed rank test.
FigUre 1 | Distribution of 64 joints treated with low-dose radiation therapy 
in 23 dogs.
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resUlTs
Demographic and clinical characteristics
Twenty-five dogs met the inclusion criteria. Represented breeds 
were Labrador Retriever (n  =  10, 40%), German Shepherd 
(n = 5, 20%), mixed breed (n = 4, 16%), Rottweiler and Golden 
Retriever (n = 2 each, 8%), Great Dane and Bernese Mountain 
Dog (n = 1 each, 4%). Males were over-represented (n = 18, 72%, 
12 intact and 6 castrated males) compared to females (n = 7, 48% 
2 intact and 5 spayed females). Mean age was 8.9 years (median 
9 years; range 2–15 years), mean weight 33.4 kg (median 32 kg; 
range 20–74 kg). The BCS was normal in 15 dogs (60%; BCS 
of 4–5/9), whereas it was increased in the remaining 10 (40%; 
BCS 7–9/9).
Clinically, 6 dogs had a single joint affected by OA (4 elbows 
and 2 stifles). The other 19 dogs had multiple (2–5) joints OA, 
but there was one primary affected joint, with marked soft tissue 
thickening, decreased ROM and pain score graded from 3 to 4. 
In these dogs, lameness grade and pain score were described for 
the most severely affected joint only. Lameness score was 4 in the 
majority of cases (n = 13, 52%), followed by 3 (n = 7, 28%), 5 
(n = 3, 12%), and 2 (n = 2, 8%). Pain score was graded as follows: 
4 in 11 dogs (44%), followed by 3 in 9 dogs (36%), 2 in 3 dogs 
(12%), and 1 in 2 dogs (8%).
Before RT, all dogs were treated as follows: 22 dogs (88%) 
received medical therapy [n = 17 non-steroid anti-inflammatory 
drugs (NSAID), n = 5 steroids, n = 8 opiates], 20 (80%) nutraceu-
tical, and 3 (12%) dogs underwent physiotherapy. Twenty-three 
dogs (92%) had combined treatments. At presentation, 13 dogs 
(52%) were treated with nutraceutical, 5 (20%) with NSAID, and 
3 (12%) with physiotherapy. In 10 dogs (40%), NSAID therapy 
was interrupted because of gastrointestinal side effects. All treat-
ments were discontinued at the beginning of RT.
Radiographs of the affected joints and thorax, complete blood 
cell count (CBC), and serum biochemistry profile were available 
for all dogs. Radiographs were evaluated by single radiologist 
(Federica Rossi). Thoracic radiographs were within normal 
limits in 9 dogs (36%), whereas in 16 dogs (64%), a diffuse, mild 
interstitial lung pattern was observed, compatible with dog’s age 
and BCS. Joint radiographs showed peri-articular osteophytosis 
(n = 60 joints, 94%), subcondral bone sclerosis (n = 49 joints, 
77%), peri-articular soft tissue thickening (n = 46 joints, 72%), 
and thinning of the joint space (n = 54 joints, 84%), CBC was 
normal in 23 dogs (92%), whereas in two cases, there was a mild 
normocytic anemia, and in one dog, mild neutrophilic leuko-
penia. Biochemistry profile showed abnormalities in 12 dogs 
(48%), including elevated renal parameters (urea, creatinine, and 
phosphor) in 4 dogs, and increased liver enzymes (ALT, AST, SAP, 
and γGT) in 9 dogs.
Treatment
General anesthesia was inducted with intravenous injection of 
propofol at the dosage of 2–4  mg/kg (Proposure® 10  mg/ml, 
Merial Italia spa, Milano) and maintained after intubation with a 
oxygen-isofluorane mixture with 2–3% isofluorane con centration.
64 joints in 25 dogs were treated (Figure 1). The most fre-
quently treated joint was the elbow (n = 34; 53%, 14 bilateral, 
and 6 monolateral), followed by the hip (n = 12, 19%, 5 bilateral 
and 2 monolateral), metacarpophalangeal joints (n =  8, 13%, 
3 bilateral and 2 monolateral), shoulder (n = 6 joints, 9%, all 
bilateral), and stifle (n = 4, 6%, 1 bilateral and 2 monolateral). 
The number of joints irradiated in the same dog was one 
(6 dogs), two (8 dogs), three (3 dogs), four (7 dogs), and five 
(1 dog). Mean anesthesia length was 20 min (range 10–30 min) 
FigUre 4 | Chronic pain index score obtained from the owner’s questioners 
before and after RT. The median value changed from 32 (95% CI: 29–33) to 
20 (95% CI: 16–20), with a significant decrease after the treatment 
(P < 0.001).
FigUre 3 | Pain score evaluated at presentation and 3 weeks after low-dose 
radiation therapy in 23 dogs. The median pain score decreased from 3 (range 
1–4) to 2 (range 1–4) after RT (P < 0.001).
FigUre 2 | Lameness score evaluated at presentation and 3 weeks after 
low-dose radiation therapy in 23 dogs. The median lameness score 
decreased from 4 (range 2–5) to 3 (range 0–3) after RT (P < 0.001).
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if 1–3 joints were irradiated and 35 min (range 30–40 min) for 
the treatment of 4–5 joints.
Because of owner’s logistical reasons, the majority of the dogs 
(n = 21, 84%) were treated over three consecutive days and, only 
in four cases, the alternate schedule was delivered.
Size of the treatment field was 10 cm × 10 cm (49 joints), 6 × 8 
(8 joints), 12 × 12 (6 joints), and 6 × 6 (1 joints). Delivered beam 
energy was 9 MeV in 3, 12 MeV in 12, and 15 MeV in 49 joints.
Follow-Up
The clinical recheck 3 weeks after RT was performed in 23 (92%) 
dogs. At this time, all showed clinical improvement (92%). A 
partial response was obtained in 16 (64%), and a complete 
response was documented in 7 (28%) animals. The median 
lameness and pain scores were, respectively, 4 and 3 before RT 
and 3 and 2 after RT. Both scores were significantly reduced after 
the treatment (P < 0.001) (Figures 2 and 3). One dog was never 
rechecked, and the owner reported that there was no improve-
ment after RT. One dog died 2 weeks after the end of RT because 
of a car accident.
Median follow-up was 437 days (95% CI: 112–762 days). At 
the end of the study, 21 dogs (84%) had died; in 8 of them, the 
clinical benefit of RT was still present at the time of death. One 
dog was euthanized because of OA, whereas 20 dogs died for 
OA-unrelated causes.
In the 23 dogs experiencing clinical improvement, this lasted 
for a median of 300  days (95% CI: 104–770). 12 dogs did not 
receive any medical therapy after RT, whereas medication was 
administered in 13 dogs after a median of 309 days after RT.
17 dogs (68%) underwent radiographic follow-up of 38 treated 
joints. The peri-articular soft tissue thickening noted in 33 examined 
elbows and stifles joint radiographs was subjectively less evident after 
RT in 22/33 joints (67%), whereas the bony changes were similar.
No acute or late side effects were observed.
24 owners completed the two questionnaires, 22 of them being 
satisfied with LDRT because of the improvement of their dogs’ 
QoL. Before LDRT, the median chronic pain index score was 32 
(95% CI: 29–33), whereas it was scored 20 3 weeks after RT (95% 
CI: 16–20), with a significant decrease after treatment (P < 0.001) 
(Figure 4). Reasons for owners complaint were lack of response 
(n = 1) and short-lasting response (n = 1).
additional lDrT Treatments
At time of symptoms recurrence, a second course of LDRT was 
offered to the owners. Four dogs (16%) were re-treated with the 
same protocol, respectively 218, 266, 39, and 1,384 days after the 
first treatment. A clinical improvement was observed again and 
lasted for a median of 418 days (range 60–1,194). One of these 
dogs, a 7 years old male Labrador Retriever, affected by a severe 
stifle OA due to cranial cruciate ligament rupture and complica-
tions after surgery, received five treatments, with a further clinical 
benefit of 150, 176, and 173 days. This dog died 48 months after 
the first LDRT for OA-unrelated causes. At the time of death, the 
lameness was still under control. Toxicity was not observed in 
dogs receiving additional LDRT.
Owner consent was obtained for all treated dogs.
DiscUssiOn
Geriatric dogs are often affected by single or multicentric OA, 
leading to chronic pain and reduced QoL, occasionally leading to 
5Rossi et al. Radiotherapy Treatment of DJD in Dogs
Frontiers in Veterinary Science | www.frontiersin.org April 2018 | Volume 5 | Article 74
the owners’ request for euthanasia. Targeted treatments are often 
not indicated or possible, and the therapeutic strategies are lim-
ited to a combination of drugs and other alternative treatments 
like nutriceutical and physiotherapy. LDRT is an adjunctive, 
non-conventional therapy, which can be offered in case of failure 
of other treatments or if medical therapy cannot be used because 
of excessive side effects or comorbidities. No data are available in 
dogs on the use of LDRT delivered to different joints and with a 
long follow-up.
The present pilot study indicates that LDRT is feasible and 
useful in dogs with multicentric joint involvement. Indeed, 92% 
of dogs affected by single or multiple joint OA and irradiated 
with LDRT showed partial or complete responses after 3 weeks. 
Notably, the clinical benefit lasted for a median of 300 days, and 
re-start of medical therapy was considered necessary after a 
median of 309 days in 13 dogs. All dogs suffered from chronic 
pain due to OA and previous treatments were insufficient to 
control the disease, or had to be interrupted because of renal or 
gastrointestinal side effects.
These results are aligned with previously reported data in 
human medicine (12–14, 27, 28). Marked and complete pain 
response has been reported in 58–91% patients irradiated for 
gonarthrosis, in 24–89% patients with coxarthrosis, and in 
63–75% with hand and finger joints OA. Partial and complete 
response for shoulder and elbow syndrome varied between 
58–100 and 63–75%, respectively (13).
In people, the most frequently treated joints are the weight-
bearing hip and stifle, suggesting that the involvement of these 
joints is highly invalidating and requires any effort to be treated 
(13). Interestingly, 84% of the dogs in the current study were 
treated for primary forelimb lameness due to shoulder, elbow, 
and metacarpophalangeal OA or a combination of these condi-
tions, and this may reflect a similar situation, since the paws of the 
forelimb support the majority of the dog’s weight as demonstrated 
by temporal–spatial gait analysis (29). This is another element 
supporting the treatment of multiple joints during the same RT 
section.
At the time of pain recurrence, LDRT was repeated in four 
dogs, with a further benefit in chronic pain control for an addi-
tional long period (median of 418  days). One dog with severe 
stifle OA received five LDRT over 48  months, for a total dose 
of 30 Gy, with a clinical benefit lasting until the dog’s death. In 
human non-malignant disorders guidelines, a second LDRT is 
recommended in the case of persisting pain or insufficient pain 
relief after 6–12 weeks, but treatments beyond a second course 
are not reported (13, 30). It is important to consider that ionizing 
radiation has the potential risk of developing secondary neoplasia 
(31). However, available data in humans indicate that cancer risk 
after RT for benign diseases of the extremities is very low and 
comparable to other routine radiologic diagnostic procedures 
(31). The main factor determining risk is the site of treatment 
(31). Careful planning is advocated if the treatment field includes 
a significant amount of red bone marrow (for example, if the 
shoulder or hips are treated), because of a low (<0.2%) potential 
risk of leukemia induction (31). Moreover, risk of developing 
basal cell carcinoma in the irradiated filed has been estimated as 
0.006% in people treated with 3 Gy at the extremities (31). Acute 
or chronic side effects were not observed in this study as well as 
in dogs receiving multiple LDRT; no dogs developed secondary 
neoplasia at the treatment site or leukemia.
Recently, the results of a single dose 10 Gy RT treatment in a 
group of five Labradors affected by elbow OA were reported (21). 
A short-term benefit was noted: force plate gait analysis before 
and after RT revealed an improvement in the weight-bearing on 
the affected limb at weeks 6 and 14. However, the clinical result 
was less evident in the long period. In the present study, Labrador 
Retriever and elbow OA were over-represented; 12 elbows in 
8 Labrador were treated (4 bilaterally and 4 monolaterally). 
Lameness grade improved in all but one dog at week 3, and the 
clinical benefit lasted for a median of 524 days; median pre- and 
posttreatment chronic pain index was 33 and 18, respectively.
Comparison of the two studies is biased by the different 
treatment efficacy assessment and different RT protocols. Due 
to the retrospective nature of the current study, objective force 
plate analysis was not performed. Efficacy evaluation was based 
on pre- and posttreatment orthopedic examination (lameness 
and pain grading) and owner observation through a validated 
chronic pain questionnaire. Although force plate analysis rep-
resents the most objective analysis to document the efficacy of 
treatment, human guidelines recommend to follow-up patients 
with physical examinations and subjective pain score assessment 
during the first year after RT (13, 30). In the current study, dogs 
were treated with a total dose of 6  Gy delivered in three frac-
tions. There are no established guidelines for RT treatment of 
small animal OA; however, recommendations for the treatment 
of painful refractory degenerative joints are available in human 
medicine, describing a maximum of 6 Gy total dose delivered in 
small (up to 1 Gy) fractions (27, 30). Based on long clinical benefit 
documented in the current study, it may be hypothesized that the 
3 × 2 Gy protocol is a better choice compared to the single dose 
10 Gy treatment. Further prospective studies including a larger 
group of dogs evaluated with force plate analysis before and after 
RT are warranted.
In addition to the lack of the force plate analysis, this study 
has some other limitations, including breed heterogeneity, and 
inhomogeneous OA causes and severity. Moreover, in 12 dogs, 
multiple joints were affected and treated. Even if a primarily 
site of lameness was always identified and objectively rechecked 
through an orthopedic examination, it is possible that the owner 
perception of the clinical benefit was influenced by the sum of a 
multi-centric pain relief. It must be emphasized that the value of 
the owner’s assessment of chronic pain through a questioners has 
been shown in veterinary literature (25, 32, 33). On the other hand, 
some investigations found that owner assessment score improved 
even in dogs treated with placebo, suggesting a caregiver placebo 
effect in this outcome measure (34, 35). Therefore, the use of mul-
tiple outcome measures combining questioner scores and clinical 
objective evaluations is recommended in clinical trials studying 
analgesic treatments for canine OA (36).
Finally, 9–15 MeV electron beam technique could be subop-
timal in dose distribution for joints located at depth exceeding 
5  cm, especially hips in large dogs and for these cases photon 
beam RT could provide better dose distribution with a clinical 
advantage. However, in this study, all dogs with hip OA showed 
a clinical improvement after RT. Moreover, photon beam RT has 
the disadvantage that positioning CT and a more time-consuming 
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planning is necessary before RT treatment, with consequent 
higher costs and longer preparation time.
In conclusion, these preliminary data support the use of LDRT 
in the management of unresponsive pain due to OA in dogs. 
Also, LDRT can be repeated without evidence of side effects with 
prolonged clinical benefit.
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